Urjana Poreci
About Urjana Poreci
Urjana Poreci is a Senior Program Manager at Seismic Therapeutic, with a diverse background in the biotechnology sector, including roles at Biogen and Alnylam Pharmaceuticals. She holds a Bachelor of Science in Biochemistry from Suffolk University.
Current Role at Seismic Therapeutic
Urjana Poreci currently serves as a Senior Program Manager at Seismic Therapeutic. She has been in this position since 2023, bringing her extensive experience in program management and scientific research to the role. Her responsibilities include overseeing various projects and ensuring alignment with the company's strategic goals.
Previous Experience at Seismic Therapeutic
Prior to her current role, Urjana Poreci worked at Seismic Therapeutic as a Program Manager from 2021 to 2023. During her tenure, she contributed to the development and management of key programs, leveraging her background in scientific research to enhance project outcomes.
Professional Background in Biotech
Urjana Poreci has a robust background in the biotechnology sector, having held several positions at prominent companies. She worked at Biogen in various roles, including Associate Scientist III in Biomarkers and Immunology Research, and Associate Scientist II. Her experience at Alnylam Pharmaceuticals included positions as Principal Associate Scientist and Senior Associate Scientist in Early Development, focusing on bioanalytical methods.
Educational Background in Biochemistry
Urjana Poreci earned her Bachelor of Science degree in Biochemistry from Suffolk University, completing her studies from 2005 to 2009. This educational foundation has supported her career in scientific research and program management within the biotechnology industry.
Career Progression in Scientific Research
Urjana Poreci's career in scientific research began at Pfizer, where she worked as a Senior Associate Scientist in Pharmacokinetics, Dynamics, and Metabolism in 2011. She then joined Biogen, where she progressed through various roles over several years, gaining expertise in biomarker research and immunology before moving to Alnylam Pharmaceuticals and eventually Seismic Therapeutic.